Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

GLP-1 anti-obesity medications are linked with improvements in testosterone levels and health outcomes for men with obesity or type 2 diabetes, researchers reported in San Francisco at ENDO 2025, the ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

LLY, NFLX, and GE lead this week???s top research picks as strong demand, growth strategies, and sector tailwinds fuel ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), Netflix, Inc ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

Additionally, new board members were brought in to oversee leadership. Among the appointments were Mike Mason, former president of Eli Lilly's diabetes and obesity business. Existing directors Tara ...

WeightWatchers has appointed Dr. Kim Boyd as chief medical officer and announced a new program focused on helping women ...

WeightWatchers announces Dr. Kim Boyd as its new chief medical officer and unveils a program to support women through ...